Suppl. Fig. S1 from Characterization of Novel Derivatives of MBQ-167, an Inhibitor of the GTP-binding Proteins Rac/Cdc42

Medina, Julia I.; Cruz-Collazo, Ailed; Maldonado, Maria del Mar; Matos Gascot, Tatiana; Borrero-Garcia, Luis D.; Cooke, Mariana; Kazanietz, Marcelo G.; Hernandez O'Farril, Eliud; Vlaar, Cornelis P.; Dharmawardhane, Suranganie

doi:10.1158/2767-9764.22546214.v1

Suppl. Fig. S1 from Characterization of Novel Derivatives of MBQ-167, an Inhibitor of the GTP-binding Proteins Rac/Cdc42

journal contribution

posted on 2023-04-04, 02:02 authored by Julia I. Medina, Ailed Cruz-Collazo, Maria del Mar Maldonado, Tatiana Matos Gascot, Luis D. Borrero-Garcia, Mariana Cooke, Marcelo G. Kazanietz, Eliud Hernandez O'Farril, Cornelis P. Vlaar, Suranganie Dharmawardhane

<p>Suppl. Fig. S1 shows percentage cell viability</p>

Funding

HHS | NIH | National Institute of General Medical Sciences (NIGMS)

DOD | U.S. Army (US Army)

Puerto Rico Science Technology and Research Trust

HHS | NIH | National Institute on Minority Health and Health Disparities (NIMHD)

HHS | NIH | National Cancer Institute (NCI)

History

Related Materials

1.
DOI - Is supplement to Characterization of Novel Derivatives of MBQ-167, an Inhibitor of the GTP-binding Proteins Rac/Cdc42

ARTICLE ABSTRACT

Targeting the related GTPases Rac and Cdc42 that regulate cancer metastasis is a viable strategy to impede metastasis of solid cancers. Herein, we describe new Rac and Cdc42 inhibitors with unique mechanisms and varying potency in different cancer cell lines. The MBQ-167 derivatives MBQ-168 and EHop-097 show promise as potential antimetastatic cancer agents.